"CHICAGO March   PRNewswire  Chrono Therapeutics http a pioneer in digital drug therapy today announced that clinical data for the companys smoking cessation technology showed a statistically significant reduction in nicotine cravings in a trial of adult male smokers. The data were presented today at the Society for Research on Nicotine  Tobaccos nd Annual Meeting. Chronos wearable transdermal drug delivery device times nicotine delivery to when smokers have their strongest cravings. For example  of all smokers reach for their first cigarette within  minutes of waking up. The Chrono Solution is designed to deliver the first dose of nicotine replacement therapy NRT shortly before a smoker wakes up and then creates a pattern of peaks and troughs of nicotine delivery throughout the rest of the day to assure the smoker has more nicotine support when cravings are predicted to be strongest. In the United States  percent of smokers want to quit but quitting is extremely difficult. In fact most people try  to  times and this includes quit attempts with standard cessation medications like nicotine patch and gum and prescription drugs like varenicline said Alan Levy Ph.D. chairman and CEO of Chrono Therapeutics. Gums and patches are designed to help manage cravings but they are only  to  percent effective. Our goal is to solve this crisis of public health with an innovative integrated smoking cessation solution and the data we presented demonstrates that we are on the right path. The clinical trial was a randomized double blinded study of  adult males who smoked  or more cigarettes per day indicating a high level of nicotine dependence. The subjects were divided into two groups. Test group subjects had nicotine administered over a hour time period via Chronos prototype device that delivered nicotine according to Chronos peaks and troughs profile. Control subjects had a placebo solution with no nicotine administered at the same intervals via the same prototype device. Across both groups subjects showed no serious adverse events or study withdrawals due to an adverse event. Skin irritation assessment showed no signs of irritation or erythema.  Cravings were assessed via three different methods the Questionnaire for Smoking Urges QSU the Mood and Physical Symptoms Scale MPSS and a single craving question each of which is a validated tool to assess cravings. When compared to subjects treated with placebo test subjects had a statistically significant and clinically meaningful reduction in cravings for all assessment methods p. p. and p. respectively. Achieving statistical significance in a subject trial is very striking and happens infrequently in biopharma so these results are very encouraging noted Wende Hutton general partner at Canaan Partners and a member of Chronos board of directors. Quitting smoking is one of the simplest ways to improve global public health but as the dismal efficacy of current therapies demonstrates it is also one of the hardest. Im very excited to be working with a company that has the potential to solve such a serious problem.   About Chrono Therapeutics Effective care of the most hardtotreat conditions requires approaches beyond simply taking medicine. Chronos team is developing the first wearable transdermal drug delivery device that optimizes drug dosing is embedded with sensor technology to track usage and is connected via Bluetooth to an evidencebased smartphone application that delivers realtime personalized behavioral support to keep users on track to achieve their goals. Chronos first application is in smoking cessation enabling smokers to overcome the worlds deadliest addiction. For more information visit  http  Media Contact Margaux StackBabich  margauxcanalecomm.com mailtomargauxcanalecomm.com SOURCE Chrono Therapeutics Related Links http"